Clinical Trial Update: Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating base editing of hematopoietic stem and progenitor cells to repair mutations causing X-linked chronic granulomatous dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease
• X-linked Chronic Granulomatous Disease

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1, Phase 2 | Status: RECRUITING